Abstract
A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dosefinding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irinotecan 160 mg/m2; oxaliplatin 80 mg/m2; 5-FU 900 mg/m2. The doselimiting toxicity was diarrhea (35% of patients) but no cases of febrile neutropenia were observed. In 30 patients assessable for response two complete (6.7%) and 18 partial (60%) responses were observed, for an overall response rate of 66.7% (α0.05, CI±7). The triplet association using this weekly alternating schedule is an active and well-tolerated outpatient regimen. Surgical removal of residual disease was considered in 5 patients and a radical resection was performed in 5 patients (14%).
| Original language | English |
|---|---|
| Pages (from-to) | 1635-1640 |
| Number of pages | 6 |
| Journal | Oncology Reports |
| Volume | 23 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2010 |
Fingerprint
Keywords
- 5-Fluorouracil
- Advanced colorectal cancer
- CPT-11
- l-OHP
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer : A dose-finding and phase II study. / Morelli, M. F.; Santomaggio, A.; Ricevuto, E.; Cannita, K.; De Galitiis, F.; Tudini, M.; Bruera, G.; Mancini, M.; Pelliccione, M.; Calista, F.; Guglielmi, F.; Martella, F.; Lanfiuti Baldi, P.; Porzio, G.; Russo, A.; Gebbia, N.; Iacobelli, S.; Marchetti, P.; Ficorella, Corrado.
In: Oncology Reports, Vol. 23, No. 6, 2010, p. 1635-1640.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer
T2 - A dose-finding and phase II study
AU - Morelli, M. F.
AU - Santomaggio, A.
AU - Ricevuto, E.
AU - Cannita, K.
AU - De Galitiis, F.
AU - Tudini, M.
AU - Bruera, G.
AU - Mancini, M.
AU - Pelliccione, M.
AU - Calista, F.
AU - Guglielmi, F.
AU - Martella, F.
AU - Lanfiuti Baldi, P.
AU - Porzio, G.
AU - Russo, A.
AU - Gebbia, N.
AU - Iacobelli, S.
AU - Marchetti, P.
AU - Ficorella, Corrado
PY - 2010
Y1 - 2010
N2 - A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dosefinding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irinotecan 160 mg/m2; oxaliplatin 80 mg/m2; 5-FU 900 mg/m2. The doselimiting toxicity was diarrhea (35% of patients) but no cases of febrile neutropenia were observed. In 30 patients assessable for response two complete (6.7%) and 18 partial (60%) responses were observed, for an overall response rate of 66.7% (α0.05, CI±7). The triplet association using this weekly alternating schedule is an active and well-tolerated outpatient regimen. Surgical removal of residual disease was considered in 5 patients and a radical resection was performed in 5 patients (14%).
AB - A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dosefinding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irinotecan 160 mg/m2; oxaliplatin 80 mg/m2; 5-FU 900 mg/m2. The doselimiting toxicity was diarrhea (35% of patients) but no cases of febrile neutropenia were observed. In 30 patients assessable for response two complete (6.7%) and 18 partial (60%) responses were observed, for an overall response rate of 66.7% (α0.05, CI±7). The triplet association using this weekly alternating schedule is an active and well-tolerated outpatient regimen. Surgical removal of residual disease was considered in 5 patients and a radical resection was performed in 5 patients (14%).
KW - 5-Fluorouracil
KW - Advanced colorectal cancer
KW - CPT-11
KW - l-OHP
UR - http://www.scopus.com/inward/record.url?scp=77951706637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951706637&partnerID=8YFLogxK
U2 - 10.3892/or-00000805
DO - 10.3892/or-00000805
M3 - Article
VL - 23
SP - 1635
EP - 1640
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 6
ER -